Vermillion Posts 11 Percent Rise in 2012 Revenues, 8 Percent Uptick in OVA1 Sales | GenomeWeb

This story has been update to include comments from a Vermillion executive.

Vermillion this week reported fourth-quarter revenues of $1.1 million, a 32 percent rise from $868,000 in Q4 2011. This beat the consensus Wall Street estimate for revenues of $900,000.

The quarterly revenue increase was driven by a 32 percent increase in sales of its OVA1 ovarian cancer diagnostic to $1 million from $755,000 in Q4 2011. License revenues were flat year over year at $113,000.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.